Rainbow Children’s Medicare Limited has released the transcript of its Q4 FY26 Earnings Conference Call, held on May 25, 2026. The call detailed the company’s financial performance, strategic initiatives, and future growth plans. Key highlights include a 24% revenue growth for Q4 FY26, driven by expanded capacity and improved operational metrics. The company also discussed its M&A strategy, project pipeline, and focus on enhancing patient experience and clinical excellence.
Rainbow Children’s Medicare Limited: Q4 FY26 Earnings Conference Call Highlights
Rainbow Children’s Medicare Limited has officially disseminated the transcript of its Q4 and full-year FY26 Earnings Conference Call, which took place on May 25, 2026. This document provides comprehensive insights into the company’s financial results and strategic outlook for the period ending March 31, 2026.
Financial Performance Overview
The company reported a robust financial performance for Q4 FY26, with operating revenue reaching INR459.9 crores, marking a significant 24% year-on-year growth. EBITDA for the quarter stood at INR144.7 crores, a 26% increase, and Profit After Tax (PAT) saw a substantial 38% growth, reaching INR78.2 crores. For the full fiscal year FY26, revenues grew by 12% to INR1,703 crores, with EBITDA increasing by 11% to INR544 crores and PAT by 15.3% to INR282 crores. Occupancy for the quarter was reported at 45.3%.
Strategic Growth and Expansion
FY26 has been a landmark year for Rainbow Children’s Medicare, characterized by the addition of nearly 500 beds, the highest annual capacity addition in its history. Investments made over the past two years are now reflecting in performance, with a focus on improving occupancies, clinical excellence, and patient experience. The company is actively pursuing its expansion plans, including the development of new hospitals and increasing capacity across existing facilities. Approximately 900 beds are currently in the execution phase, expected to be completed within 2.5 years.
Key Projects Underway
- The regional hub hospital in Coimbatore (130 beds) is under construction, with operations expected to commence in H2 FY28.
- Gurugram projects include the Sector 56 facility (125 beds) aiming for H2 FY28 operations and a Sector 44 hub (325 beds) targeted for Q1 FY29.
- Statutory approvals are secured for a 150-bed greenfield hub hospital in Pune.
- A lease agreement is in place for an 80-bed spoke hospital in Bangalore.
- An agreement for a 100-bed build-to-suit hospital in Central Indore is in the permission stage.
M&A and Geographic Expansion
The company continues to evaluate acquisition opportunities that align with its philosophy and offer scalability. The M&A strategy focuses on assets with at least 50 operational beds and the potential to scale up. Rainbow is also exploring expansion into new geographies, identifying emerging cities with strong long-term growth potential. The approach is driven by the attractiveness of opportunities rather than specific geographic preferences.
Operational and Clinical Focus
Technology is identified as a central element in evolving the operational model, with the implementation of a new CRM platform and Hospital Information System (HIS). The company is focused on strengthening operational capabilities to improve lead conversion and patient engagement. Rainbow remains committed to maintaining its leadership in pediatric healthcare, expanding its service offerings, and enhancing clinical depth across its network. The average length of stay (ALOS) remains stable at approximately 2.7 days, considered best-in-industry.
Future Outlook
Looking ahead, Rainbow Children’s Medicare anticipates continued growth, aiming for an aspirational 20% growth in the current year while maintaining margins. The company is strategically working to reduce dependence on seasonal demand and diversify its service portfolio. The fertility business is projected to grow at approximately 25% year-on-year for the next three years. The management expressed optimism about the long-term growth opportunity and the ability to create sustainable value for all stakeholders.
Key Financial Figures (Q4 FY26 vs. Q4 FY25)
- Revenue: INR459.9 crores (+24%)
- EBITDA: INR144.7 crores (+26%)
- PAT: INR78.2 crores (+38%)
Key Financial Figures (Full Year FY26 vs. FY25)
- Revenue: INR1,703 crores (+12%)
- EBITDA: INR544 crores (+11%)
- PAT: INR282 crores (+15.3%)
The company also noted that international patient revenue remained flat at approximately INR 28.9 crores for FY26, while the IVF business contributed INR60 crores for the full year, representing 3.7% of total revenue.
Source: BSE
